Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
Determine time-to-progression (TTP) for an escalating dose schedule for subjects with
progressive metastatic renal cell carcinoma treated with sorafenib